ALLO
Allogene Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +2.5% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 31.02K | $43,421 | n/a | n/a |
| Q2 2026 | 78 | -3 | 183.62M | $382.24M | +6 | −10 |
| Q1 2026 | 84 | +8 | 106.47M | $259.25M | +11 | −3 |
| Q4 2025 | 76 | +2 | 91.09M | $124.76M | +2 | n/a |
| Q3 2025 | 16 | 0 | 74.87M | $92.84M | +1 | −1 |
| Q2 2025 | 13 | 0 | 69.68M | $78.74M | n/a | n/a |
| Q1 2025 | 10 | +1 | 41.70M | $60.89M | +2 | −1 |
| Q4 2024 | 9 | -2 | 35.46M | $75.54M | n/a | −2 |
| Q3 2024 | 10 | 0 | 29.49M | $82.58M | n/a | n/a |
| Q2 2024 | 10 | n/a | 28.78M | $67.06M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 6.90M | 0.0% | $19.31M | 0.0% | Held | 2 | SEC ↗ |
| 2 | PRIMECAP Management ✦ | 5.67M | 0.0% | $15.87M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 5.04M | +106.0% | $14.11M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | T. Rowe Price ✦ | 4.84M | -16.4% | $13.55M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 3.23M | +14.4% | $9.04M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 2.80M | -5.5% | $7.83M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 642.01K | -63.3% | $1.80M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Millennium Management ✦ | 258.00K | +43.6% | $722,406 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 90.33K | -62.4% | $252,910 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 10 | AQR Capital Management ✦ | 33.59K | +23.1% | $94,050 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 207 holders, 182.71M shares, $425.90M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 29.70K sh · $62,958
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology